首页> 中文期刊> 《中国现代医生》 >静脉放血联合低分子肝素治疗高原地区慢性肺源性心脏病高黏血症患者疗效观察

静脉放血联合低分子肝素治疗高原地区慢性肺源性心脏病高黏血症患者疗效观察

         

摘要

Objective To investigate the therapeutic effect of intravenous bloodletting combined with low molecular weight heparin in the treatment of chronic pulmonary heart disease and hyperviscosity in plateau area. Methods 84 patients with chronic pulmonary heart disease complicated with hyperviscosity from plateau area were randomly divided into the control group (40 patients) and the observation group (44 patients). In the two groups, on the basis of routine treatment (anti-infection, anti -asthma, oxygen inhalation, and correction of heart failure), the observation group was further given intravenous bloodletting combined with low molecular weight heparin calcium. The changes of respiratory rate, content of venous hemoglobin, hematocrit and arterial partial pressure of oxygen before and after treatment were monitored and statistically analyzed. Results After treatment, the respiratory rate, content of hemoglobin, hematocrit and PaO2 in the observation group were significantly better than those in the control group (P<0. 0l). Conclusion Intra-venous bloodletting combined with low molecular weight heparin is more effective than conventional treatment method in the treatment of chronic pulmonary heart disease and hyperviscosity in plateau area.%目的 探讨静脉放血联合低分子肝素对高原地区慢性肺源性心脏病高黏血症患者的治疗效果.方法 将 84例来自高原地区的慢性肺源性心脏病高黏血症的患者,随机分为对照组(40例)和观察组(44例),两组在常规治疗(抗感染、平喘、吸氧、纠正心衰)基础上,观察组加用静脉放血联合低分子肝素钙治疗,监测两组治疗前后的呼吸次数、静脉血红蛋白含量、红细胞压积及动脉血氧分压变化并做统计学处理.结果 治疗后观察组呼吸次数、血红蛋白含量、红细胞压积及Pa02改善明显优于对照组(P<0.0l).结论 静脉放血联合低分子肝素治疗高原地区慢性肺源性心脏病高黏血症较传统治疗方法效果更佳.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号